Shortly after he became CEO of Bayer AG in 2023, CEO Bill Anderson began waging war against bureaucracy to make the life ...

Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company pioneering a breakthrough non-invasive treatment approach for amyotrophic lateral sclerosis (ALS), is pleased to ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

Naheed Mangi, a former Stanford coordinator, was found guilty of tampering with a breast cancer study database.

On this episode of Fortune’s Leadership Next podcast, co-hosts Diane Brady, executive editorial director of the Fortune CEO ...

The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, ...

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.